Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Neurotrope Inc (NQ: NTRP )

0.9720 USD +0.0269 (+2.85%)
Official Closing Price Updated: 4:33 PM EST, Nov 24, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 427,800
Open 0.9500
Bid (Size) 0.9720 (1)
Ask (Size) 0.9780 (8)
Prev. Close 0.9451
Today's Range 0.9200 - 0.9780
52wk Range 0.6808 - 3.850
Shares Outstanding 7,907,527
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
Spin-Off Distribution is Conditional Upon the Closing of Neurotrope's Proposed Merger with Metuchen Pharmaceuticals 
From PR Newswire
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
- Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant - 
From PR Newswire

Performance

YTD
+1.24%
+1.24%
1 Month
-13.21%
-13.21%
3 Month
-10.83%
-10.83%
6 Month
-32.03%
-32.03%
1 Year
+14.35%
+14.35%

More News

Read More
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
From PR Newswire
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
From PR Newswire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - FNJN, NTRP, GRUB
From ACCESSWIRE
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
From PR Newswire
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
From PR Newswire
Neurotrope Announces Investor Update Conference Call
From PR Newswire
Hercules Capital Reports Second Quarter 2020 Financial Results
From Business Wire News Releases
IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - WMGI, MINI, NTRP
From ACCESSWIRE
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.